Home  »  Trending   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Amicus Therapeutics Inc. (FOLD)

Amicus Therapeutics Inc. (NASDAQ:FOLD) went up by 2.65% from its latest closing price compared to the recent 1-year high of $12.96. The company’s stock price has collected 2.94% of gains in the last five trading sessions. MarketWatch.com reported on 09/06/22 that Billionaire Joe Edelman’s biotech hedge fund hit with SEC charges for not disclosing SPAC conflicts

Is It Worth Investing in Amicus Therapeutics Inc. (NASDAQ :FOLD) Right Now?

Plus, the 36-month beta value for FOLD is at 0.90. Opinions of the stock are interesting as 8 analysts out of 13 who provided ratings for Amicus Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The average price from analysts is $14.45, which is $3.59 above the current price. FOLD currently public float of 251.87M and currently shorts hold a 8.60% ratio of that float. Today, the average trading volume of FOLD was 3.15M shares.

FOLD’s Market Performance

FOLD stocks went up by 2.94% for the week, with a monthly drop of -8.35% and a quarterly performance of 9.92%, while its annual performance rate touched -1.09%. The volatility ratio for the week stands at 5.56% while the volatility levels for the past 30 days are set at 5.16% for Amicus Therapeutics Inc. The simple moving average for the period of the last 20 days is -4.55% for FOLD stocks with a simple moving average of 11.66% for the last 200 days.

Analysts’ Opinion of FOLD

Many brokerage firms have already submitted their reports for FOLD stocks, with Morgan Stanley repeating the rating for FOLD by listing it as a “Equal-Weight.” The predicted price for FOLD in the upcoming period, according to Morgan Stanley is $14 based on the research report published on September 09th of the current year 2022.

Goldman, on the other hand, stated in their research note that they expect to see FOLD reach a price target of $11. The rating they have provided for FOLD stocks is “Neutral” according to the report published on April 13th, 2022.

SVB Leerink gave a rating of “Outperform” to FOLD, setting the target price at $16 in the report published on January 14th of the current year.

FOLD Trading at -3.75% from the 50-Day Moving Average

After a stumble in the market that brought FOLD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.20% of loss for the given period.

Volatility was left at 5.16%, however, over the last 30 days, the volatility rate increased by 5.56%, as shares sank -9.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.25% lower at present.

During the last 5 trading sessions, FOLD rose by +2.94%, which changed the moving average for the period of 200-days by -2.43% in comparison to the 20-day moving average, which settled at $11.32. In addition, Amicus Therapeutics Inc. saw -5.97% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at FOLD starting from Crowley John F, who sale 10,468 shares at the price of $10.66 back on Sep 15. After this action, Crowley John F now owns 856,897 shares of Amicus Therapeutics Inc., valued at $111,628 using the latest closing price.

Campbell Bradley L, the President & CEO of Amicus Therapeutics Inc., sale 5,470 shares at $11.29 during a trade that took place back on Sep 01, which means that Campbell Bradley L is holding 689,618 shares at $61,764 based on the most recent closing price.

Stock Fundamentals for FOLD

Equity return is now at value -102.50, with -32.20 for asset returns.

Is FedEx Corporation (FDX) a Keeper?

FedEx Corporation (NYSE:FDX) went up by 1.55% from its latest closing price compared to the recent 1-year high of $266.79. The company’s stock price has